Studies show that the money did not contribute to innovation.
Jung et al 19 [Emily H.; She is a first-year medical student at Emory School of Medicine in Atlanta and a former research assistant at the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital; Alfred Engelberg; He is a retired pharmaceutical intellectual property attorney and philanthropist; Aaron S. Kesselheim; is a professor of medicine at Harvard Medical School and director of PORTAL; STAT News; “Do large pharma companies provide drug development innovation? Our analysis says no”; https://www.statnews.com/2019/12/10/large-pharma-companies-provide-little-new-drug-development-innovation/]//kaviWaRu
To test that claim, we examined the provenance of the highest-selling prescription medicines of Pfizer and Johnson & Johnson, the two largest pharmaceutical and biotechnology companies in 2018.
We found that these large pharmaceutical companies did not actually invent most of the drugs they sell. Indeed, it appears they have already reduced their investment in the discovery of new medicines to the point where the threat of additional reductions rings hollow and is no longer a persuasive reason for opposing legislation to lower drug prices.